AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05578521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebralcare pills
Description: a dose of 2 packages, twice a day of Cerebralcare pills
Study NCT05578521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cerebralcare pills placebo
Description: Cerebralcare pills placebo will be administrated at the same rate with experimental group
Study NCT05349461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete patellofemoral articular contact
Description: The patellofemoral condition is in constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
Study NCT05349461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incomplete patellofemoral articular contact
Description: The patellofemoral condition is in no constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
Study NCT05134974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentolamine Ophthalmic Solution 0.75%
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Study NCT05134974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Ophthalmic Solution Vehicle
Description: Phentolamine Ophthalmic Solution Vehicle
Study NCT05164523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour rhythm Holter
Description: Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.
Study NCT05164523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 36 item Short Form Survey (SF-36)
Description: Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.
Study NCT04248010 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: neuroConn DC-Stimulator MR
Description: standard tDCS, active \& sham
Study NCT04248010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neuroConn DC-Stimulator MR
Description: standard tDCS, active \& sham
Study NCT04248010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soterix MxN HD-tES
Description: HD-tDCS, active \& sham
Study NCT04248010 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix MxN HD-tES
Description: HD-tDCS, active \& sham
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length=28 days)
Study NCT06740630 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 20
Description: The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
Study NCT06740630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxneuvance
Description: The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib will be administered by mouth twice a day during each 28-day cycle
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle
Study NCT05659420 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor
Description: aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
Study NCT05659420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor
Description: aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
Study NCT05659420 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor
Description: aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle
Study NCT05280483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021 with fed state
Description: 25 mg ABSK021 (1x25 mg ABSK021 capsule) with food
Study NCT05280483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021 with fasted state
Description: 25 mg ABSK021 (1x25 mg ABSK021 capsule) without food
Study NCT05806671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off
Study NCT05806671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 320mg/day orally continuously
Study NCT05806671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle
Study NCT05770531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection for banking
Study NCT05770531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05770531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05770531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05770531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05770531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection for ctDNA evaluation
Study NCT05770531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given by IV
Study NCT05857228 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic sinus surgery (ESS)
Description: Endoscopic sinus surgery for removal of nasal polyps and sinus tissue.
Study NCT04819672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Training associated with Partial Blood Flow
Description: 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
Study NCT04819672 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low Intensity Training associated with Partial Blood Flow-Sham
Description: 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
Study NCT04889703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% Trichloroacetic acid peel
Description: Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments at 4 week intervals.
Study NCT04889703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% Salicylic acid peel
Description: Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
Study NCT06075615 — intervention group
Intervention type: DRUG
Intervention: dacomitnib
Description: patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Description: LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
Study NCT04931342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle
Study NCT06560801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Randomization will take place at visit 1 to either the group receiving standard care and dapagliflozin or standard care only.
Study NCT04757220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive tasks with EEG recording
Description: questionnaires and cognitives tasks
Study NCT04757220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive tasks with EEG recording
Description: questionnaires and cognitives tasks
Study NCT05387603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing.
Study NCT05387603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTATOC
Description: The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing.
Study NCT05387603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
Study NCT05997797 — intervention group
Intervention type: OTHER
Intervention: FAAM
Description: The FAAM is made out of two subscales including ADL and Sports subscales that have a complete score of 84 and 32, individually
Study NCT04968821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Participants randomized to the physical activity intervention will receive a Fitbit and be enrolled in Fitabase (Fitbit tracking system). Participants will also participate in 8 tele-health sessions with a physical therapist. Sessions will involve setting weekly physical activity goals and reviewing the participant's physical activity on the Fitbit tracking system.
Study NCT04968821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual postoperative care includes surgeon-directed lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
Study NCT06429592 — intervention group
Intervention type: OTHER
Intervention: education
Description: nursing care practice
Study NCT06559085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laproscopic posterior mesh rectopexy (Wells or LPMR)
Description: After complete rectal mobilization, a mesh is inserted between the sacrum and the posterior rectum, sutured into the rectum, and fixed to the promontory. The mortality rates ranged from 0% to 1.2%, and recurrence rates ranged from 0% to 11% There was an overall improvement in continence (74%-100%), with conflicting results regarding constipation. New-onset constipation in 5% to 44% of patients was reported
Study NCT06559085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic lateral mesh rectopexy (Orr-Loygue)
Description: This procedure involves complete mobilization of the rectum with two mesh strips sutured laterally to the rectal wall on both sides, and they were suspended to the promontory. There are several studies on this procedure using a laparoscopic approach. Lechaux et al. performed laparoscopic Orr-Loygue rectopexy in 35 patients. Incontinence improved in 27% of patients, and constipation improved in 19% but worsened in 27%. The recurrence rate was 3% (1/35) after a mean follow-up of 36 months. A study on 46 patients with laparoscopic Orr-Loygue procedure with posterior mobilization found a significant reduction in incontinence score after 1 year, but there were no changes in the use of laxatives. The recurrence rate was 4% after a median follow-up of 1.5 years
Study NCT06046430 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: The same assessments will be made to participants in both groups.
Study NCT06561035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opiate Sparing
Description: Subjects will receive medications in the Opiate Sparing arm for pain control.
Study NCT06561035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opiate Based
Description: Subjects will receive medications in the Opiate Based arm for pain control.
Study NCT06524219 — intervention group
Intervention type: PROCEDURE
Intervention: unilateral intrafascial resection
Description: Conducting unilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
Study NCT06524219 — intervention group
Intervention type: PROCEDURE
Intervention: bilateral intrafascial resection
Description: Conducting bilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
Study NCT06524219 — intervention group
Intervention type: PROCEDURE
Intervention: bilateral extrafascial resection
Description: Conducting bilateral extrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
Study NCT05698589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Focused Therapy
Description: CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, ...) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, ...). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.
Study NCT05698589 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ending Self Stigma
Description: Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals
Study NCT06563258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex Balance Training
Description: Sixty Subjects of both genders aged 40-60 years old with grade 2 knee osteoarthritis years will diagnosed by orthopedists they will assigned randomly into three groups:~* Group A Will receive WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.~* Group B will receive Biobex training and traditional exercises Total time of training was 10 minutes each set is 3 minutes with 20-second rest intervals~* Group C Patients will receive only traditional exercises, 3 sessions per week for four weeks. a good general guideline is 2-3 sets of 10-15 repetitions for each exercise.
Study NCT06563258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A vibration device
Description: WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.
Study NCT06563258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercises
Description: 1. Stretch exercises (flexibility exercise) Rectus femoris, Iliotibial band, Hamstring and self-stretch for calf muscle (3sets, each stretch 30 sec hold, between each set 5sec rests).~2. Strengthen exercises(resistance exercise)~   1. Isometric Exercises for quadriceps (10 rep,3sets)~  2. Hip abductors strengthening 45 degree (10 rep,3sets)~  3. Hip extensor strengthening 15 degree (10 rep,3sets)~  4. Straight leg raising 45-70 degree (10 rep,3sets)~  5. Short arc knee extension (10 rep,3sets)
Study NCT06242145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel tablet
Description: Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT06242145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT06443151 — intervention group
Intervention type: PROCEDURE
Intervention: Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid)
Description: The brachial artery in the non-dominant arm will be catheterized to infuse endothelium-dependent vasodilator acetylcholine, endothelium-independent vasodilator nitroprusside, and antioxidant ascorbic acid at concentrations to have isolated effect in the forearm.
Study NCT06443151 — intervention group
Intervention type: PROCEDURE
Intervention: venous occlusion plethysmography
Description: Whole forearm blood flow will be measured by mercury-strain gauge while venous occlusion is applied to the forearm and hand by rapid-cuff inflation to sub-arterial pressures. Changes in whole forearm blood flow with be measured at baseline, endothelial agonists, and removal of oxidative stress via acorbic acid.